Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 19/20 | 0.77 |
| ▸ | ABL1 | P00519 | 2/20 | 0.66 |
| ▸ | ABL2 | P42684 | 1/20 | 0.66 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.66 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.66 |
| ▸ | RAF1 | P04049 | 1/20 | 0.61 |
| ▸ | BRAF | P15056 | 1/20 | 0.61 |
| ▸ | EPHB2 | P29323 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5733797 | 0.87 | MAPK14 (1.00) | MAPK14ABL1ABL2MAPK8MAPK11 | |
| SCHEMBL4298900 | 0.85 | MAPK14 (0.78) | MAPK14ABL1ABL2MAPK8MAPK11 | |
| SCHEMBL2616949 | 0.85 | MAPK14 (1.00) | MAPK14ABL1ABL2MAPK8MAPK11 | |
| SCHEMBL2083472 | 0.84 | MAPK14 (1.00) | MAPK14ABL1ABL2MAPK8MAPK11 | |
| SCHEMBL2083892 | 0.84 | MAPK14 (1.00) | MAPK14ABL1ABL2MAPK8MAPK11 | |
| SCHEMBL27621815 | 0.83 | MAPK14 (0.72) | MAPK14MAPK11BRAF | |
| SCHEMBL5743898 | 0.82 | MAPK14 (1.00) | MAPK14ABL1ABL2MAPK8MAPK11 | |
| SCHEMBL5733076 | 0.81 | MAPK14 (1.00) | MAPK14ABL1ABL2MAPK8MAPK11 | |
| SCHEMBL668606 | 0.81 | MAPK14 (1.00) | MAPK14ABL1ABL2MAPK8MAPK11 | |
| SCHEMBL2616952 | 0.80 | MAPK14 (0.80) | MAPK14ABL1ABL2MAPK8MAPK11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7625915-B2 | Inhibition of RAF kinase using aryl and heteroaryl substituted heterocyclic ureas | BAYER HEALTHCARE LLC (US) | 2009-12-01 | — | — | US | disclosed |
| US-20080009527-A1 | INHIBITION OF RAF KINASE USING ARYL AND HETEROARYL SUBSTITUTED HETEROCYCLIC UREAS | BAYER HEALTHCARE LLC | 2008-01-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080009527-A1 | INHIBITION OF RAF KINASE USING ARYL AND HETEROARYL SUBSTITUTED HETEROCYCLIC UREAS | BRAF, RAF1, ARAF | MAPK14 166/4885ABL1 146/4885ABL2 440/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.